Hong Kong Auto Stock News

Modern Dental Group (SEHK:3600) has opened FY 2025 with first half revenue of HK$1,834.8 million and basic EPS of HK$0.30, setting a clear reference point for how its earnings story is developing. The company has seen revenue move from HK$1,701.8 million and EPS of HK$0.23 in 1H 2024 to HK$1,662.2 million and EPS of HK$0.21 in 2H 2024, before reaching HK$1,834.8 million and EPS of HK$0.30 in 1H 2025, backed by trailing 12 month earnings growth of 46.3% and a net margin that has stepped up to...

CSSC (Hong Kong) Shipping (SEHK:3877) has put fresh numbers on the table for FY 2025, with first half revenue of HK$1.7b and basic EPS of HK$0.18 setting the tone for how you assess the latest move in profitability. The company has seen revenue shift from HK$1.58b in 1H 2024 to HK$1.31b in 2H 2024 and then to HK$1.7b in 1H 2025, while basic EPS moved from HK$0.22 to HK$0.13 and then to HK$0.18 over the same stretch. This gives you a clear read on the recent earnings pattern. With net profit...

China State Construction International Holdings (SEHK:3311) FY 2025 earnings recap China State Construction International Holdings (SEHK:3311) has laid out a steady set of FY 2025 numbers, with fourth quarter revenue of about C¥24.8b and basic EPS of C¥0.37, while trailing twelve month revenue stood at roughly C¥100.4b and EPS at C¥1.64. Over recent periods, the company has seen quarterly revenue move from around HK$25.1b with basic EPS of HK$0.36 in Q4 2024 to HK$26.4b with EPS of HK$0.47 in...

Gaush Meditech (SEHK:2407) has opened FY 2025 with first half revenue of C¥653.1 million and basic EPS of C¥0.26, setting the tone for how its earnings story is evolving after a strong run in recent years. The company has seen revenue move from C¥642.0 million in 1H 2024 to C¥786.4 million in 2H 2024 and C¥653.1 million in 1H 2025, while basic EPS shifted from C¥0.19 to C¥0.43 and then to C¥0.26 over the same periods. This gives a clear view of how the top and bottom line have tracked...

Mao Geping Cosmetics (SEHK:1318) has just posted fresh FY 2025 numbers, with first half revenue of CNY 2,588.2 million and basic EPS of CNY 1.37. This is set against trailing twelve month revenue of CNY 5,050.5 million and EPS of CNY 2.46, alongside net earnings growth of 36.7% over the past year. Over recent periods, the company has seen revenue move from CNY 1,971.5 million in 1H 2024 to CNY 1,913.2 million in 2H 2024 and then to CNY 2,588.2 million in 1H 2025. Net income (excluding extra...

Ocumension Therapeutics (SEHK:1477) opened FY 2025 with first half revenue of C¥294.0 million and a basic EPS loss of C¥0.17, alongside trailing 12 month revenue of C¥804.4 million and a basic EPS loss of C¥0.20 that keeps the business in loss making territory. Over the last three reported half year periods, the company has seen revenue move from C¥167.6 million in 1H 2024 to C¥249.7 million in 2H 2024 and then to C¥294.0 million in 1H 2025. Basic EPS losses moved from C¥0.23 to C¥0.17 and...

Ju Teng International Holdings (SEHK:3336) has released its FY 2025 first half numbers, with revenue of HK$2,714.7 million and a basic EPS loss of HK$0.09, alongside net income excluding extra items of a HK$79.1 million loss. Over recent periods, the company has seen revenue move from HK$2,999.3 million in 1H 2024 to HK$3,027.0 million in 2H 2024 and HK$2,714.7 million in 1H 2025, while basic EPS shifted from a HK$0.08 loss in 1H 2024 to a HK$0.55 loss in 2H 2024 and a HK$0.09 loss in the...

Marketingforce Management (SEHK:2556) has kicked off FY 2025 with first half revenue of CN¥928.3 million and EPS of CN¥0.15, as investors weigh the latest numbers against a current share price of HK$35.48. The company has seen revenue move from CN¥739.4 million in 1H FY 2024 to CN¥819.1 million in 2H FY 2024 and CN¥928.3 million in 1H FY 2025, while EPS shifted from a loss of CN¥4.33 in 1H FY 2024 to a loss of CN¥0.24 in 2H FY 2024 before turning to a modest profit in the latest period. This...

Grand Pharmaceutical Group (SEHK:512) has opened FY 2025 with first half revenue of HK$6.1b and basic EPS of HK$0.33, setting the tone for how its earnings story is evolving after a year of shifting margins. Over recent periods the company has seen revenue move from HK$6.0b in 1H 2024 to HK$5.6b in 2H 2024 and then to HK$6.1b in 1H 2025. Basic EPS tracked HK$0.44, HK$0.26 and HK$0.33 across the same halves, giving investors a clearer view of how the top line and EPS are aligning with a...

China Resources Beverage (Holdings) (SEHK:2460) has opened FY 2025 with first half revenue of C¥6.2b and basic EPS of C¥0.34, set against a share price of HK$9.01 as investors assess how the softer headline numbers sit within the broader story. Over the same half year in 2024, revenue was C¥7.6b and basic EPS was C¥0.56. The latest release follows a period where the company had already been growing earnings at about 8.6% a year over five years, while its trailing net margin moved from 12.1%...

Everest Medicines (SEHK:1952) has reported its FY 2025 first half results with revenue of C¥446.1 million and a net loss of C¥249.8 million, translating to basic EPS of a C¥0.77 loss. The company’s revenue moved from C¥301.5 million in the first half of 2024 to C¥405.2 million in the second half of 2024, and then to C¥446.1 million in the first half of 2025. Over the same periods, net losses shifted from C¥632.4 million to C¥409.0 million and then to C¥249.8 million. Trailing twelve month...

Xtep International Holdings (SEHK:1368) has just posted its FY 2025 results with first half revenue of C¥6.8b and basic EPS of C¥0.35, set against trailing twelve month revenue of C¥14.2b and EPS of about C¥0.51 that point to steady earnings power. Over the past few first half periods, the company has seen revenue move from C¥6.5b in 2023 to C¥6.4b in 2024 and C¥6.8b in 2025, while basic EPS shifted from C¥0.26 to C¥0.34 and then to C¥0.35. This gives investors a clear sense of how...

Full year earnings set the tone for Consun Pharmaceutical Group Consun Pharmaceutical Group (SEHK:1681) released its full year 2025 results, reporting sales of CNY 3,417.36 million and net income of CNY 1,078.07 million, both higher than the prior year. Basic earnings per share from continuing operations came in at CNY 1.27, and diluted earnings per share were CNY 1.26, compared with CNY 1.11 and CNY 1.09 respectively a year earlier. See our latest analysis for Consun Pharmaceutical...

Ximei Resources Holding (SEHK:9936) has put up solid headline numbers for FY 2025, with first half revenue of C¥954.2 million and basic EPS of C¥0.26, set against trailing twelve month revenue of about C¥2.24 billion and EPS of C¥0.48 that comes with 38.2% earnings growth over the past year. The company has seen revenue move from C¥902.6 million in 1H FY 2024 to C¥919.5 million in 2H FY 2024 and then to C¥954.2 million in 1H FY 2025, while net income excluding extra items went from C¥62.3...

LVGEM (China) Real Estate Investment (SEHK:95) has released its FY 2025 first half results, reporting revenue of C¥1,039.7 million and a basic EPS loss of C¥0.31, alongside trailing 12 month revenue of C¥1,866.0 million and a basic EPS loss of C¥1.46. Over recent periods, the company has seen revenue move from C¥1,942.8 million in 1H 2024 to C¥1,771.1 million in 2H 2024 and then to C¥1,039.7 million in 1H 2025, with basic EPS losses of C¥0.30, C¥0.70 and C¥0.31 respectively. This sets up a...

Maoyan Entertainment (SEHK:1896) has reported its FY 2025 first half with revenue of C¥2.47b and basic EPS of C¥0.16, against a backdrop where trailing twelve month revenue sits at C¥4.63b and EPS at C¥0.49. Over the last three reported half year periods, revenue has moved from C¥2.17b in 1H 2024 to C¥1.91b in 2H 2024 and then to C¥2.47b in 1H 2025. Over the same periods, basic EPS has shifted from C¥0.25 to a loss of C¥0.09 and then to C¥0.16, setting a clear earnings rhythm for investors to...

Glorious Sun Enterprises (SEHK:393) has reported its FY 2025 first half results with revenue of HK$489.6 million and basic EPS of HK$0.021434, against a backdrop of trailing twelve month revenue of HK$976.7 million and basic EPS of HK$0.0501. Over recent periods the company has seen revenue move from HK$529.9 million in 1H FY 2024 to HK$380.2 million in 2H FY 2024 and HK$489.6 million in 1H FY 2025, while basic EPS has ranged from HK$0.016156 to HK$0.024463 and then HK$0.021434. This sets the...

People's Insurance Company (Group) of China (SEHK:1339) has wrapped up FY 2025 with Q4 revenue of C¥169.0b, alongside a small loss that translated into basic EPS of C¥0.01, while on a trailing twelve month basis EPS stood at C¥1.04 on revenue of C¥625.0b. Over the past year, the company has seen its trailing EPS move from C¥0.95 to C¥1.04 and revenue from C¥581.5b to C¥625.0b, outlining a picture where modest EPS growth, a 7.4% net margin and an already priced in growth outlook are key angles...

Neutech Group (SEHK:9616) has reported its FY 2025 first half results with revenue of CNY 924.9 million and basic EPS of CNY 0.32, while trailing twelve month revenue sits at CNY 2.0 billion with basic EPS of CNY 0.63. This gives investors a clear snapshot of recent top and bottom line performance. The company has seen revenue move between CNY 968.1 million and CNY 1.1 billion over the previous two half year periods, with basic EPS ranging from CNY 0.29 to CNY 0.43, so the latest print slots...

APT Electronics (SEHK:2551) has just reported its FY 2025 first half results, with revenue of C¥1.1b and basic EPS of C¥0.02, alongside trailing twelve month figures showing revenue of C¥2.6b and EPS of C¥0.13. Over recent half year periods, the company has seen revenue move from C¥843.2m to C¥1.1b, while basic EPS shifted from C¥0.06 to C¥0.02. This frames a set of results where top line progress sits beside tighter earnings. For investors, the key question now is how much of this revenue...

Smart Globe Holdings (SEHK:1481) has reported FY 2025 first half revenue of HK$102.5 million with basic EPS of HK$0.008259, set against a trailing twelve month picture that shows revenue of HK$204.9 million and EPS of HK$0.0077. Over recent periods the company has seen revenue move from HK$50.5 million in 1H FY 2024 to HK$67.1 million in 2H FY 2024 and then to HK$102.5 million in 1H FY 2025. EPS shifted from a loss of HK$0.005557 per share to a loss of HK$0.006206 and then to a profit of...

PICC Property and Casualty (SEHK:2328) has opened FY 2025 with first half revenue of C¥259.3b and basic EPS of C¥1.10, setting the tone for another full year of results under close watch. The company has seen revenue move from C¥242.2b in the first half of 2024 to C¥272.3b in the second half of 2024 and then to C¥259.3b in the first half of 2025, while trailing twelve month EPS has shifted from C¥1.45 at the end of 2024 to C¥1.82 by the latest period. This frames an earnings story that...

S.A.S. Dragon Holdings (SEHK:1184) has put fresh numbers on the table for FY 2025, with first half revenue of HK$12.6b and basic EPS of HK$0.42 backed by net income of HK$263.5m. The company has seen revenue move from HK$13.6b in the first half of FY 2024 to HK$14.1b in the second half and now HK$12.6b in the first half of FY 2025, while EPS shifted from HK$0.53 to HK$0.27 and now HK$0.42. This sets up a results story where modest margins and earnings trends are front and center for investors...

Alphamab Oncology FY 2025 results in focus Alphamab Oncology (SEHK:9966) has posted its FY 2025 numbers with first half revenue of C$319.4 million and basic EPS of C$0.02, providing an indication of how the rest of the year may shape up for margins. The company has seen revenue move from C$173.6 million in 1H 2024 to C$466.5 million in 2H 2024 and then to C$319.4 million in 1H 2025, while EPS shifted from a loss of C$0.05 in 1H 2024 to C$0.22 in 2H 2024 and C$0.02 in the latest period. This...